Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude.
The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.
Essential Job Functions
Reporting to the Vice President, Market Access, the Senior Director, US Managed Markets will collaborate across departments to lead the Managed Markets group dedicated to the launch and life cycle management of Kura Oncology products in the United States.
- Works closely with the Vice-President, Market Access and other senior Commercial leaders to outline the direction forward for our Payer and Access approach in the United States and articulate this direction to the organization and field team
- Lead the US Managed Markets field facing customer teams
- Align with Pricing & Contract Management to formulate access enhancing proposals; lead the review and approval of these proposals; participate/lead proper internal forum to ensure success within the financial objectives of the company
- Partner with Market Access, Marketing, Field Sales and Medical colleagues to ensure the overall patient access approach meets the needs of patients in the current market environment
- Serve as internal Payer / Managed Markets subject matter expert on business development proposals and/or on future company products in the United States
- Define the value proposition for various customer segments including Medicare, Commercial, Integrated Delivery Networks, VA, DOD, and commercial payers
- Work closely with the Senior Director of Brand Strategy and HCP Marketing to translate the professional market development campaign into the appropriate equivalent for the Managed Markets audience; develop concept, message platform, and collateral
- Lead the strategic planning and coordination for coverage of our products with Payers and other potential Managed Care Organizations
- Work closely with the Executive Director of Patient Access and Distribution and the Senior Director of GPO and Strategic Accounts to implement a group purchasing organization (GPO) strategy
- Lead the strategy and management of negotiations and contracting within the Gross to Net (GTN) budget with Market Access peers in Pricing and Contract Management
- Develop the US Managed Markets convention plan
- Lead and design the Managed Markets customer facing model in coordination with Insights and Analytics leadership, that is aligned to Kura’s commercial strategy
- Other related duties as assigned
JOB SPECIFICATIONS:
- BA/BS or comparable experience
- 10+ years working in the pharma/biotech space with experience including:
- Managed Markets and/or channel strategy experience – must have a strong understanding of the US payer/reimbursement landscape
- Oncology and or oral rare disease experience
- Managing vendors – independent consultants and advertising agencies
- Ability to travel 10-20%
- MBA/MS or comparable experience
- Experience marketing Medicare/Part D drugs
- Experience marketing products that go through specialty distribution/specialty pharmacy
- Strategic leadership roles in other commercial functions that will enhance the leadership and communication capabilities and executive presence within the Market Access and Commercial organization. (Marketing, Field Sales, etc)
The base range for a Senior Director is $253,000 - $293,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.
Kura’s Values that are used for candidate selection and performance assessments:
- We work as one for patients
- We are goal-focused and deliver with excellence
- We are science-driven courageous innovators
- We strive to bring out the best in each other and ourselves
The Kura Package
- Career advancement/ development opportunities
- Competitive comp package
- Bonus
- 401K + Employer contributions
- Generous stock options
- ESPP Plan
- 20 days of PTO to start
- 18 Holidays (Including Summer & Winter Break)
- Generous Benefits Package with a variety of plans available with a substantial employer match
- Paid Paternity/Maternity Leave
- In-Office Catered lunches
- Home Office Setup
- Lifestyle Spending Stipend
- Commuter Stipend (Boston Office)
- Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!
Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines.
Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001).
The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001).
For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.
